| Carbon nanotubes for delivery of small molecule drugs BS Wong, SL Yoong, A Jagusiak, T Panczyk, HK Ho, WH Ang, G Pastorin Advanced drug delivery reviews 65 (15), 1964-2015, 2013 | 626 | 2013 |
| Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models CY Tan, RC Lai, W Wong, YY Dan, SK Lim, HK Ho Stem cell research & therapy 5, 1-14, 2014 | 584 | 2014 |
| Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness F Peng, MI Setyawati, JK Tee, X Ding, J Wang, ME Nga, HK Ho, DT Leong Nature nanotechnology 14 (3), 279-286, 2019 | 418 | 2019 |
| Nanomaterial scaffolds for stem cell proliferation and differentiation in tissue engineering C Zhao, A Tan, G Pastorin, HK Ho Biotechnology advances 31 (5), 654-668, 2013 | 295 | 2013 |
| Nanoparticles' interactions with vasculature in diseases JK Tee, LX Yip, ES Tan, S Santitewagun, A Prasath, PC Ke, HK Ho, ... Chemical Society Reviews 48 (21), 5381-5407, 2019 | 269 | 2019 |
| Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study YT Cheung, T Ng, M Shwe, HK Ho, KM Foo, MT Cham, JA Lee, G Fan, ... Annals of Oncology 26 (7), 1446-1451, 2015 | 231 | 2015 |
| Public awareness of diabetes mellitus in Singapore HL Wee, HK Ho, SC Li Singapore medical journal 43 (3), 128-134, 2002 | 228 | 2002 |
| Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a … HK Ho, S Pok, S Streit, JE Ruhe, S Hart, KS Lim, HL Loo, MO Aung, ... Journal of hepatology 50 (1), 118-127, 2009 | 220 | 2009 |
| Bioactivation and hepatotoxicity of nitroaromatic drugs UA Boelsterli, HK Ho, S Zhou, K Yeow Leow Current drug metabolism 7 (7), 715-727, 2006 | 207 | 2006 |
| Thin films of functionalized multiwalled carbon nanotubes as suitable scaffold materials for stem cells proliferation and bone formation TR Nayak, L Jian, LC Phua, HK Ho, Y Ren, G Pastorin ACS nano 4 (12), 7717-7725, 2010 | 206 | 2010 |
| Metabolism‐related pharmacokinetic drug− drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations YL Teo, HK Ho, A Chan British journal of clinical pharmacology 79 (2), 241-253, 2015 | 161 | 2015 |
| Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib WC Teng, JW Oh, LS New, MD Wahlin, SD Nelson, HK Ho, ECY Chan Molecular pharmacology 78 (4), 693-703, 2010 | 129 | 2010 |
| Oxidative stress by inorganic nanoparticles JK Tee, CN Ong, BH Bay, HK Ho, DT Leong Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 8 (3 …, 2016 | 125 | 2016 |
| Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines JE Ruhe, S Streit, S Hart, CH Wong, K Specht, P Knyazev, T Knyazeva, ... Cancer research 67 (23), 11368-11376, 2007 | 115 | 2007 |
| Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum (IV) prodrug of cisplatin SL Yoong, BS Wong, QL Zhou, CF Chin, J Li, T Venkatesan, HK Ho, V Yu, ... Biomaterials 35 (2), 748-759, 2014 | 114 | 2014 |
| Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis YL Teo, HK Ho, A Chan Cancer treatment reviews 39 (2), 199-206, 2013 | 101 | 2013 |
| Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer T Ng, SM Teo, HL Yeo, M Shwe, YX Gan, YT Cheung, KM Foo, MT Cham, ... Neuro-oncology 18 (2), 244-251, 2015 | 98 | 2015 |
| Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma W Poh, W Wong, H Ong, MO Aung, SG Lim, BT Chua, HK Ho Molecular cancer 11, 1-10, 2012 | 91 | 2012 |
| Navigating albumin-based nanoparticles through various drug delivery routes YL Tan, HK Ho Drug discovery today 23 (5), 1108-1114, 2018 | 87 | 2018 |
| The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells A Roidl, P Foo, W Wong, C Mann, S Bechtold, HJ Berger, S Streit, ... Oncogene 29 (10), 1543-1552, 2010 | 87 | 2010 |
